In another phase two clinical trial, patients with resected IIIA N2 NSCLC harboring EGFR mutations (either exon 19 deletion or L858R point mutation) were assigned to four cycles of carboplatin-pemetrexed, followed or not by gefitinib for 6 months. This evidence concerns the gene EGFR and non-small cell lung carcinoma.